Axsome Therapeutics Inc. (AXSM)
NASDAQ: AXSMHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 172.97 0.00%
AXSM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.06B
- Forward P/E
- 36.66
- EPS (TTM)
- -$3.74
- Dividend yield
- None
- 52-week range
- 117.30 – 260.19
- Day range
- 172.48 – 177.91
- Volume / Avg
- 887.28K / 703.40K
- Beta
- —
- Shares outstanding
- 52.38M
- Next earnings
- Nov 2, 2026
52-week range
AXSM stock today
Axsome Therapeutics (AXSM) closed at $172.97 on Oct 7, down 0.79% (-$1.37), versus the S&P 500's 0.22% decline. Shares are 33.5% below their 52-week high of $260.19, set on Jun 18, 2026 and 47.5% above the 52-week low of $117.30, in the middle of the past year's range. AXSM is down 4.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 47.8%.
Axsome Therapeutics has posted a net loss over the last twelve months (EPS of -$3.74), so its P/E ratio is not meaningful. Axsome Therapeutics's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Axsome Therapeutics
Company profileAxsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Herriot Tabuteau M.D.
- Headquarters
- New York, NY
- Employees
- 1,346
- IPO year
- 2015
- Website
- axsome.com
Financial highlights
Full financialsIn fiscal 2025, Axsome Therapeutics generated $638.5 million in revenue, up 65.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Axsome Therapeutics reported a net loss of $183.2 million, compared with a loss of $287.2 million a year earlier. Gross margin was 92.6% (up from 91.4%) and operating margin -26.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $638.50M | $385.69M | $270.60M | $0 | — |
| Growth | +65.55% | +42.53% | — | — | — |
| Net income | $-183.17M | $-287.22M | $-239.24M | $-187.13M | $-130.40M |
| EPS (diluted) | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$284.63+64.55%
- Strong buy 3
- Buy 18
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $-0.56
- Last reported (Q2 2026)
- Aug 10, 2026
- EPS actual vs est.
- $-0.99 vs —
AXSM news
All AXSM newsAxsome Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs AXSM |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs AXSM |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs AXSM |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs AXSM |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs AXSM |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs AXSM |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs AXSM |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs AXSM |
Indexes, lists and sector
Appears in lists
Axsome Therapeutics stock FAQ
What is Axsome Therapeutics's stock price today?
AXSM last traded at $172.97 as of Oct 7, 4:00 PM EDT, down 0.79% on the day. Prices are delayed at least 15 minutes.
When is Axsome Therapeutics's next earnings date?
Axsome Therapeutics is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $-0.56.
Who is Axsome Therapeutics's CEO?
Dr. Herriot Tabuteau M.D. is the chief executive officer of Axsome Therapeutics Inc., which has about 1,346 employees.
What is the AXSM 52-week high?
The 52-week high for AXSM is $260.19 and the 52-week low is $117.30. The stock is currently 33.5% below its high.